Genmab stock enters new phase after three cancer-drug wins


Morgan Stanley starts Genmab stock coverage with USD 42 ...

Genmab reports USD 4.24 billion DARZALEX sales and BofA ...

HC Wainwright raises target for Genmab stock from USD 40 ...

Genmab stock gains 5.32 percent on Rina-S data

Genmab stock after-hours at EUR 319.90: minus 0.03 percent ...

Genmab reports Rina-S results. Genmab stock falls 1.95 percent ...

Genmab outlines three Phase 3 readouts and Genmab stock ...

Genmab stock after-hours at EUR 308.25: minus 1.99 percent ...